{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-000988","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-07-30T12:15:52+00:00","discovered_at":"2026-07-30T12:20:00.332498+00:00","generated_at":"2026-07-30T12:20:11.075209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's","bullets":["Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.","Cash and equivalents $127.4M as of March 31, 2026, up from $102.6M at Sept 30, 2025; expected to fund operations into mid-to-late FY2028.","Opened IND for early Alzheimer's disease with FDA in March 2026; ADME study expected Q3 2026, DDI study underway.","Aligned with FDA on Phase 3 Rett syndrome protocol for adults; plans to discuss adding pediatric patients.","Submitted plan to regain Nasdaq compliance on July 20, 2026 (Listing Rule 5250(c)(1))."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000988","json":"https://secwatch.observer/filing/0001731122-26-000988.json","markdown":"https://secwatch.observer/filing/0001731122-26-000988.md","text":"https://secwatch.observer/filing/0001731122-26-000988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/0001731122-26-000988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/e7813_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T12:20:11.075209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}